AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29244956 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 13
Study 27785923 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMX) prophylaxis
Number of subjects: 40
Study 27785923 — intervention group
Group type: COMPARATOR
Intervention: Lactobacilli prophylaxis
Number of subjects: 40
Study 25305538 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by undergraduates alone
Number of subjects: 0
Study 21932036 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Androgen Blockade (MAB)
Number of subjects: 63
Study 21932036 — intervention group
Group type: COMPARATOR
Intervention: More Maximal Androgen Blockade (mMAB)
Number of subjects: 63
Study 20508478 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV and MMRV vaccine
Number of subjects: 325
Study 20508478 — intervention group
Group type: COMPARATOR
Intervention: DTPa‐HBV‐IPV/Hib and MMRV vaccines
Number of subjects: 325
Study 20508478 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV and DTPa‐HBV‐IPV/Hib vaccine
Number of subjects: 325
Study 17494311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroxide phonophoresis
Number of subjects: 0
Study 17494311 — intervention group
Group type: EXPERIMENTAL
Intervention: Phinalgel phonophoresis
Number of subjects: 0
Study 18317317 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring group experiences
Number of subjects: 0
Study 18317317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropes course experiences
Number of subjects: 0
Study 15315997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU) daily
Number of subjects: 617
Study 12230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum isolate IOWA
Number of subjects: 3
Study 12230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum isolate TAMU
Number of subjects: 3
Study 12230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum isolate UCP
Number of subjects: 3
Study 12230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of the three isolates (IOWA, TAMU, UCP)
Number of subjects: 3
Study 12230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Random oocyst from the larger population of strains
Number of subjects: 3
Study 9296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (300 mg) administered in the evening after a high fat meal
Number of subjects: 12
Study 9296325 — intervention group
Group type: COMPARATOR
Intervention: Pranlukast (300 mg) administered in the morning after a high fat meal
Number of subjects: 12
Study 8191447 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosage of chloramphenicol eyedrops (0.5% eye drops, one drop hourly/every two hours for three days, thereafter every 4‐6 hours)
Number of subjects: 152
Study 8191447 — intervention group
Group type: COMPARATOR
Intervention: Simplified dosage of chloramphenicol eyedrops (four times a day)
Number of subjects: 152
Study 3075473 — intervention group
Group type: EXPERIMENTAL
Intervention: Euro‐Collins' solution (ECS; n = 9)
Number of subjects: 18
Study 3075473 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution (RS; n = 9)
Number of subjects: 18
Study 31096958 — intervention group
Group type: EXPERIMENTAL
Intervention: Green exercise and balneotherapy (GEBT)
Number of subjects: 80
Study 31096958 — intervention group
Group type: EXPERIMENTAL
Intervention: Green exercise (GE)
Number of subjects: 80
Study 31096958 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 80
Study 28236262 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 132
Study 28236262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 132
Study 28236262 — intervention group
Group type: COMPARATOR
Intervention: Control (rest only; noise-canceling headphones)
Number of subjects: 132
Study 28236262 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention and Aromatherapy
Number of subjects: 132
Study 26220533 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 16
Study 26220533 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 16
Study 22617860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 255 mg daily
Number of subjects: 338
Study 22617860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 340 mg daily
Number of subjects: 338
Study 22617860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 425 mg daily
Number of subjects: 338
Study 22617860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 510 mg daily
Number of subjects: 338
Study 22617860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 22015077 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir 150 mg once daily
Number of subjects: 724
Study 22015077 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 724
Study 19490952 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 310
Study 19490952 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 310
Study 17766504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity practices (3 practices)
Number of subjects: 20
Study 17766504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity practices (17 practices)
Number of subjects: 20
Study 17766504 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 20
Study 16305290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter-orange dried-fruit extract (450 mg standardized to 27 mg of m- or p-synephrine)
Number of subjects: 18
Study 16305290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12001541 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin
Number of subjects: 0
Study 12001541 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin/oral phenprocoumon
Number of subjects: 0
Study 9459074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals
Number of subjects: 99
Study 9459074 — intervention group
Group type: COMPARATOR
Intervention: Normotensive individuals
Number of subjects: 99
Study 9459074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals and Normotensive individuals
Number of subjects: 99
Study 7534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 10 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 12)
Number of subjects: 36
Study 7534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 13)
Number of subjects: 36
Study 7534217 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg.kg‐1 (n = 11)
Number of subjects: 36
Study 2774849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (phototherapy) for individuals with subsyndromal seasonal affective disorder, 5 hours divided between morning and evening.
Number of subjects: 20
Study 2774849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (phototherapy) for individuals with subsyndromal seasonal affective disorder, 2 hours exposure.
Number of subjects: 20
Study 2774849 — intervention group
Group type: COMPARATOR
Intervention: Bright light exposure (phototherapy) for healthy individuals (controls).
Number of subjects: 20
Study 334477 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg flurbiprofen daily
Number of subjects: 30
Study 334477 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg indomethacin daily
Number of subjects: 30
Study 334477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of flurbiprofen and indomethacin
Number of subjects: 30
Study 30768161 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 day high-dose dual therapy (esomeprazole 40 mg three times daily and amoxicillin 750 mg four times daily for 14 days)
Number of subjects: 240
Study 30768161 — intervention group
Group type: COMPARATOR
Intervention: 7 day non-bismuth quadruple therapy (esomeprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days)
Number of subjects: 240
Study 30768161 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 day high-dose dual therapy
Number of subjects: 240
Study 30768161 — intervention group
Group type: COMPARATOR
Intervention: 7 day non-bismuth quadruple therapy
Number of subjects: 240
Study 28593734 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI-tss device integrated with guidance, assurance, counselling and behavioural changes
Number of subjects: 40
Study 28593734 — intervention group
Group type: COMPARATOR
Intervention: Guidance, assurance, counselling and behavioural changes
Number of subjects: 40
Study 25462663 — intervention group
Group type: COMPARATOR
Intervention: Stimulant Craving Questionnaire (STCQ) for methamphetamine users
Number of subjects: 301
Study 25462663 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant Craving Questionnaire (STCQ) for cocaine users
Number of subjects: 301
Study 23504241 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 62
Study 23504241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21856349 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV co-administered with HepB
Number of subjects: 741
Study 21856349 — intervention group
Group type: COMPARATOR
Intervention: HepB alone
Number of subjects: 741
Study 21856349 — intervention group
Group type: COMPARATOR
Intervention: HPV alone
Number of subjects: 741
Study 19687085 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cold Provocation Test
Number of subjects: 176
Study 17291993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 45
Study 17291993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 45
Study 17291993 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 45
Study 15482068 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict monitoring in an attentional task
Number of subjects: 0
Study 15482068 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 scalp potential
Number of subjects: 0
Study 15482068 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-error conflict detection
Number of subjects: 0
Study 11465582 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-10 minute discussion led by anesthesiologists about end-of-life care communication
Number of subjects: 0
Study 11465582 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative anesthesia screening
Number of subjects: 0
Study 11465582 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-10 minute discussion led by anesthesiologists
Number of subjects: 0
Study 8167653 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise glucose ingestion (100 g glucose polymer drink)
Number of subjects: 13
Study 8167653 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise glucose ingestion with potassium chloride (3 g KCl)
Number of subjects: 13
Study 8167653 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose drink alone)
Number of subjects: 13
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. injection of 8 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. injection of 10 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. injection of 20 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of 2 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of 4 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of 8 micrograms alsactide
Number of subjects: 10
Study 2850604 — intervention group
Group type: COMPARATOR
Intervention: placebo (isotonic saline)
Number of subjects: 10
Study 31231369 — intervention group
Group type: COMPARATOR
Intervention: Tear lysozyme concentration (Lys-C) in individuals with URTI
Number of subjects: 26
Study 31231369 — intervention group
Group type: COMPARATOR
Intervention: Tear lysozyme secretion rates (Lys-SR) in individuals with URTI
Number of subjects: 26
Study 31231369 — intervention group
Group type: COMPARATOR
Intervention: Tear lactoferrin secretion rates (Lf-SR) in individuals with URTI
Number of subjects: 26
Study 31231369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear AMP secretion rates post-exercise
Number of subjects: 26
Study 31231369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear AMP concentrations during dehydration
Number of subjects: 26
Study 27933616 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 92
Study 27933616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 92
Study 27933616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 27933616 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 92
Study 26025212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling plus brochures
Number of subjects: 158
Study 26025212 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored print brochures
Number of subjects: 158
Study 23691830 — intervention group
Group type: EXPERIMENTAL
Intervention: System 2 (stereo headphones)
Number of subjects: 18
Study 23691830 — intervention group
Group type: EXPERIMENTAL
Intervention: System 3 (stereo headphones and a bone conduction vibrator)
Number of subjects: 18
Study 23691830 — intervention group
Group type: COMPARATOR
Intervention: System I (three loudspeakers)
Number of subjects: 18
Study 21517963 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative questionnaire about SIDS
Number of subjects: 292
Study 19335435 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied twice daily for 8 weeks
Number of subjects: 8
Study 19335435 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no treatment)
Number of subjects: 8
Study 19335435 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 8
Study 16732472 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition enhancement training (SCET) plus standard psychiatric rehabilitation training
Number of subjects: 34
Study 16732472 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric rehabilitation training only
Number of subjects: 34
Study 14672612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 I.U. per day for 3 months)
Number of subjects: 51
Study 14672612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 14672612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 51
Study 11385906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0
Study 11385906 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (organ preserving or reconstructive techniques)
Number of subjects: 0
Study 11385906 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interaction
Number of subjects: 0
Study 9508170 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus prednisone (IFN/P)
Number of subjects: 233
Study 9508170 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN)
Number of subjects: 233
Study 8071269 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 75
Study 8071269 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg zolpidem
Number of subjects: 75
Study 8071269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3052188 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of Rhinalar (less propylene glycol)
Number of subjects: 122
Study 3052188 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of Rhinalar
Number of subjects: 122
Study 31450175 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope view
Number of subjects: 96
Study 31450175 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller blade
Number of subjects: 96
Study 31450175 — intervention group
Group type: COMPARATOR
Intervention: Miller and Wis-Hipple and direct C-MAC views
Number of subjects: 96
Study 30657434 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SBI
Number of subjects: 45
Study 30657434 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 45
Study 30657434 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SBI plus text messaging
Number of subjects: 45
Study 28656612 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric vestibular stimulation (CVS) device (TNM™), 3-month treatment
Number of subjects: 0
Study 28656612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 25979566 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g whey protein
Number of subjects: 10
Study 25979566 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g whey protein
Number of subjects: 10
Study 25979566 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g whey protein
Number of subjects: 10
Study 25979566 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g whey protein
Number of subjects: 10
Study 25979566 — intervention group
Group type: COMPARATOR
Intervention: All conditions (20, 40, 60, 80 g whey protein)
Number of subjects: 10
Study 23052408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus administered simultaneously with tacrolimus
Number of subjects: 27
Study 23052408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus administered staggered after tacrolimus
Number of subjects: 27
Study 23052408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus administered simultaneously with sirolimus
Number of subjects: 27
Study 23052408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus administered staggered before sirolimus
Number of subjects: 27
Study 21526394 — intervention group
Group type: EXPERIMENTAL
Intervention: FOUR score
Number of subjects: 176
Study 21526394 — intervention group
Group type: COMPARATOR
Intervention: GLS/GCS
Number of subjects: 176
Study 19222510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonabersat 20 mg daily for 2 weeks and 40 mg daily for a further 10 weeks
Number of subjects: 123
Study 19222510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonabersat
Number of subjects: 123
Study 19222510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 16516013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study 14747388 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCT) in nephrology
Number of subjects: 430
Study 14747388 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard guidelines and checklists for trial reporting
Number of subjects: 430
Study 12846595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (3mg)
Number of subjects: 24
Study 12846595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ximelagatran (24mg)
Number of subjects: 24
Study 12846595 — intervention group
Group type: COMPARATOR
Intervention: Activated partial thromboplastin time (APTT) ratio
Number of subjects: 24
Study 10958095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10958095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.3 mg x kg(‐1))
Number of subjects: 160
Study 10958095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (1 mg x kg(‐1))
Number of subjects: 160
Study 10958095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimenhydrinate and metoclopramide
Number of subjects: 160
Study 8836333 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (local nasal immunotherapy with birch-alder allergens in powder form)
Number of subjects: 22
Study 8836333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 22
Study 1430296 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax mouthwash
Number of subjects: 33
Study 1430296 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 33
Study 4072649 — intervention group
Group type: EXPERIMENTAL
Intervention: Meticillin 1 g X 4 intravenously on the day of operation
Number of subjects: 50
Study 4072649 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 50
Study 3310513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator rate of 120/min
Number of subjects: 32
Study 3310513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator rate of 120/min using Sechrist ventilators
Number of subjects: 32
Study 3310513 — intervention group
Group type: COMPARATOR
Intervention: Ventilator rates of 30/min and 60/min
Number of subjects: 32
Study 30277101 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 331
Study 28768627 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant factor VIII (rFVIII)
Number of subjects: 235
Study 28768627 — intervention group
Group type: COMPARATOR
Intervention: plasma-derived concentrates (pdFVIII)
Number of subjects: 235
Study 25652341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps‐In‐Noise test (GIN)
Number of subjects: 31
Study 25652341 — intervention group
Group type: COMPARATOR
Intervention: Gap Detection Test (GDT)
Number of subjects: 31
Study 23902481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² administered once a week for 4 weeks)
Number of subjects: 197
Study 23902481 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide followed by azathioprine (cyclophosphamide for 3 to 6 months followed by azathioprine for 12 to 15 months)
Number of subjects: 197
Study 23902481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (for patients with relapsing disease at baseline)
Number of subjects: 197
Study 21816030 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS, S/AS01 malaria vaccine
Number of subjects: 0
Study 19394194 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Treatment Model (DT)
Number of subjects: 147
Study 19394194 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-Consultation Treatment Model (CC)
Number of subjects: 147